Gerlach Herwig, Toussaint Susanne
Department of Anesthesia, Critical Care and Pain Management, Vivantes - Klinikum Neukoelln Rudower Strasse 48, D-12351 Berlin Germany.
F1000 Med Rep. 2010 May 24;2:40. doi: 10.3410/M2-40.
Although several successful clinical trials in the last 2-3 years have been greeted with enthusiasm by intensivists, severe sepsis and septic shock still have increasing incidence and more or less unchanged mortality. Within the last few years, the progress in sepsis research covering definitions, epidemiology, pathophysiology, diagnosis, and standard and adjunctive therapy as well as general measures such as treatment bundles is encouraging. In this report, a small selection of recent publications, focusing on the current discussion of activated protein C as well as the relevance of the Surviving Sepsis Campaign bundle therapy, is presented and the possible impact on clinical routine is discussed.
尽管在过去两到三年里，多项成功的临床试验受到了重症监护医生的热烈欢迎，但严重脓毒症和脓毒性休克的发病率仍在上升，死亡率或多或少保持不变。在过去几年中，脓毒症研究在定义、流行病学、病理生理学、诊断、标准和辅助治疗以及诸如治疗集束等一般措施方面取得的进展令人鼓舞。在本报告中，精选了一些近期的出版物，重点关注目前对活化蛋白C的讨论以及脓毒症存活策略集束治疗的相关性，并探讨其对临床常规可能产生的影响。
